Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the cl

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of contraception drugs by company and by stage as well as a summary of the latest news and developments in this area.

Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently the

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of erectile dysfunction drugs by company and by stage as well as a summary of the latest news and developments in this area.

This report provides full analysis of the current and future infertility drug market, with indication-specific forecasts to 2016 for marketed and key pipeline drugs. Analysis is supplemented with opinion leader comment

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of female sexual dysfunction drugs by company and by stage as well as a summary of the latest news and developments in this area.

The HRT market peaked in 2001 at $3.5 billion across the seven major markets. The Women`s Health Initiative findings released in 2002 showing that HRT use was associated with an increased breast cancer and cardiovascular disease risk precipitated a maj

Female sexual dysfunction affects an estimated 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. The condition can affect a woman`s desire, ability to become aroused and orgasm and m

In this report the reader will be introduced to an analysis of current and prospective markets, drug research and development, and company activities within the hormonal contraception and infertility therapy sectors.

The report provides a detailed analysis of the sexual disorders therapy area to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market.

Identify the latest dealmaking trends in your field

The hormonal contraceptive market grew by 4.2% from 2004 to $5.0 billion in 2005. Market growth was driven in part by the strong uptake of Schering AG’s Yasmin and Organon’s NuvaRing which fulfill key strategies: additional indications and

The erectile dysfunction market grew 3.5% from 2005 to be worth $1.95 billion in 2005 and is almost entirely composed of sales from three brands: Viagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil). Despite the dominance of these products,